| Compound  | 2    | 2,2-Dimethylpropanoic acid<br>(pivalic acid)<br>C5H10O2                             | Factsheet   |
|---|------|---|---|
| Parameter   | Note | Comments  | Value / descriptor                                    |
| EU-LCI value and status                               |      |   |   |
| EU-LCI value  | 1    | Mass/volume [µg/m³]   | 2100  |
| EU-LCI status   | 2    | Draft/final   | Final   |
| EU-LCI year of issue                                  | 3    | Year when the EU-LCI value has been issued  | 2018  |
| General information                                   |      |   |   |
| CLP-INDEX-No.   | 4    | INDEX   | -   |
| EC-No.  | 5    | EINECS – ELINCS - NLP   | 200-922-5   |
| CAS-No.   | 6    | Chemical Abstracts Service number   | 75-98-9   |
| Harmonised CLP classification                         | 7    | Human health risk related classification  | -   |
| Molar mass and conversion<br>factor                   | 8    | [g/mol] and [ppm – mg/m <sup>3</sup> ]  | 102.13<br>1 ppm = 4.20 mg/m <sup>3</sup>              |
| Key data / database                                   |      |   |   |
| Key study, author(s), year                            | 9    | Critical study with lowest relevant effect level                                    | -   |
| Read across compound                                  | 10   | Where applicable  | Acetic acid CAS 64-19-7<br>Propionic acid CAS 79-09-4 |
| Species   | 11   | Rat, human, etc.  | -   |
| Route/type of study                                   | 12   | Inhalation, oral feed, etc.   | -   |
| Study length  | 13   | Days, subchronic, chronic   | -   |
| Exposure duration                                     | 14   | Hrs/day, days/week  | -   |
| Critical endpoint                                     | 15   | Effect(s), site of  | -   |
| Point of departure (POD)                              | 16   | LOAEC*L, NOAEC*L, NOEC*L,<br>benchmark dose, etc.                                   | -   |
| POD value   | 17   | [mg/m <sup>3</sup> ] or [ppm] or [mg/kg <sub>BW</sub> ×d]                           | 0.5 ppm   |
| Assessment factors (AF)                               | 18   |   |   |
| Adjustment for exposure<br>duration                   | 19   | Study exposure<br>hrs/day, days/week  | -   |
| Study Length  | 20   | $sa \rightarrow sc \rightarrow c$<br>(R8-5)   | -   |
| Route-to-route extrapolation                          | 21   |   | -   |
| Dose-response   | 22 a | Reliability of dose-response,<br>LOAEL → NOAEL                                      | -   |
|   | 22 b | Severity of effect (R 8-6d)   | -   |
| Interspecies differences                              | 23 a | Allometric<br>Metabolic rate <i>(R8-3)</i>  | -   |
|   | 23 b | Kinetic + dynamic   | -   |
| Intraspecies differences                              | 24   | Kinetic + dynamic<br>Worker - general population                                    | -   |
| Sensitive population                                  | 25   | Children or other sensitive groups  | -   |
| Other adjustment factors<br>Quality of whole database | 26   | Completeness and consistency<br>Reliability of alternative data ( <i>R8-6 d,e</i> ) | -   |

| Result                        |    |  |                |
|-------------------------------|----|--|----------------|
| Summary of assessment factors | 27 | Total Assessment Factor (TAF)                | -              |
| POD/TAF                       | 28 | Calculated value (µg/m <sup>3</sup> and ppb) | -              |
| Molar adjustment factor       | 29 | Used in read-across                          | Not applicable |
| Rounded value                 | 30 | [µg/m³]                                      | 2100           |
| Additional comments           | 31 |  |                |
|                               |    |  |                |
| Rationale section             | 32 |  |                |
|                               | •  |  |                |

Pivalic acid has low acute toxicity. The oral LD50 in male rats is approximately 2000 mg/kg. No animals died after 4-hour inhalation exposure at 5.30 mg/L (ECHA Registration dossier).

All rabbits dermally exposed to pivalic acid (4 hours, semioccluded) elicited erythema, ranging from severe to slight. Eye instillation of 0.2 mL caused severe eye irritation (ECHA registration dossier).

n-Pivalic acid was not mutagenic in the Salmonella/microsome bacterial mutagenicity assay (Ames test), with or without metabolic activation (ECHA registration dossier).

No adverse effects were seen in rats given 30 mg/kg daily for 28 days by oral gavage. At higher doses (100 and 300 mg/kg/day), rats were observed to sneeze and produce a dark nasal discharge, probably due to a mild irritant effect (ECHA registration dossier).

No reproductive toxicity studies are available.

The adverse effect of concern is irritation. No studies addressing irritation or sensory irritation from inhalation exposure were found. However, for sensory irritation there is only a slight trend of increased potency from formic acid (C1) to butyric acid (C4) (Nielsen *et al.* 2007).

The EU-LCI value for pivalic acid (C5) is therefore derived by read-across using the EU-LCI for propionic (C3) acid of 500 ppb (0.5 ppm, for acetic acid the same value was derived) as the point of departure.

The resulting EU-LCI is  $(4.20 \times 500 = ) 2100 \,\mu g/m^3$ .

No data on odour detection thresholds were found.

## **References:**

ECHA Registration dossier <u>https://echa.europa.eu/de/registration-dossier/-/registered-dossier/18932/7/3/3</u>. Last accessed on 10.02.2021.

Nielsen GD, Wolkoff P, Alarie Y (2007) *Sensory irritation: Risk assessment approaches*. Reg Toxicol Pharmacol 48: 6-18.